Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 55,100 shares, a drop of 43.7% from the March 15th total of 97,800 shares. Based on an average daily trading volume, of 357,500 shares, the short-interest ratio is presently 0.2 days. Approximately 0.8% of the company’s stock are sold short.
Biofrontera Stock Performance
Shares of Biofrontera stock traded down $0.01 during trading hours on Thursday, reaching $0.82. 9,216 shares of the company were exchanged, compared to its average volume of 908,055. The firm has a market cap of $7.30 million, a PE ratio of -0.36 and a beta of 0.36. Biofrontera has a 1 year low of $0.65 and a 1 year high of $2.22. The stock’s fifty day moving average is $0.93 and its 200 day moving average is $0.97.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of Biofrontera in the 4th quarter valued at about $48,000. AIGH Capital Management LLC raised its holdings in Biofrontera by 61.8% in the fourth quarter. AIGH Capital Management LLC now owns 811,097 shares of the company’s stock valued at $884,000 after acquiring an additional 309,663 shares in the last quarter. Finally, Rosalind Advisors Inc. lifted its stake in Biofrontera by 63.9% in the fourth quarter. Rosalind Advisors Inc. now owns 811,918 shares of the company’s stock worth $885,000 after acquiring an additional 316,428 shares during the last quarter. 10.08% of the stock is owned by institutional investors and hedge funds.
About Biofrontera
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
See Also
- Five stocks we like better than Biofrontera
- What is a penny stock? A comprehensive guide
- Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
- With Risk Tolerance, One Size Does Not Fit All
- Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
- What Do S&P 500 Stocks Tell Investors About the Market?
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
